{"id":"W3157675313","doi":"10.1136/jitc-2021-002535","title":"Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis","year":2021,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"National Center for Advancing Translational Sciences; Canadian Cancer Society; ECOG-ACRIN Cancer Research Group; National Cancer Institute; National Institutes of Health; American College of Radiology Imaging Network; Bristol-Myers Squibb","keywords":"Ipilimumab; Medicine; Rash; Internal medicine; Adverse effect; Adjuvant; Melanoma; Oncology; Multivariate analysis; Proportional hazards model; Immunotherapy; Cancer","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007880651,0.0002896872,0.001263827,0.0004499921,0.000106351,0.00002378399,0.0001319643,0.0001177694,0.0001759201],"category_scores_gemma":[0.00004519815,0.0002069025,0.0003875246,0.0009105054,0.00007444124,0.0003259851,0.00002354867,0.0003119193,2.097976e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004762414,"about_ca_system_score_gemma":0.0004003704,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001705576,"about_ca_topic_score_gemma":0.0025086,"domain_scores_codex":[0.9973347,0.0001560216,0.001182993,0.0003029536,0.0006787897,0.0003444966],"domain_scores_gemma":[0.9975162,0.0001750827,0.001196615,0.0004045716,0.000641731,0.00006582036],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0283076,0.0009516537,0.9178069,0.00009059403,0.01147839,0.00003793983,0.001509242,0.0002879367,0.0305058,0.000001147075,0.00003079111,0.008991976],"study_design_scores_gemma":[0.0284076,0.002625652,0.9507692,0.0004469589,0.001746017,0.00005035563,0.001793097,0.00006003375,0.01278791,0.000007153015,0.001061145,0.0002448801],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9884503,0.009991237,0.0001229224,0.0002951139,0.0002200524,0.0008087466,0.00008641843,0.00001160664,0.0000136094],"genre_scores_gemma":[0.9928402,0.005025281,0.0009456712,0.0001216945,0.00003775855,0.00007034118,0.00001566779,0.00005946998,0.0008839467],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03296226,"threshold_uncertainty_score":0.8437238,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02425938821284489,"score_gpt":0.3273518728818649,"score_spread":0.30309248466902,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}